The purpose of this research study is to evaluate the efficacy (how well the drug works), safety and tolerability (the side effects) of cariprazine compared to placebo (an inactive substance) in subjects with major depressive disorder who are also receiving an approved antidepressant. 18-65 years of age. Participation will be upto 19 weeks with 12 study visits to Duke study center. Compensation will be upto $420. All study related procedures and study drug will be provided free of charge.

For more information, contact Nabila Lateef at 919-684-9701.